1. Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome
- Author
-
Faycal Guedj, Sarah E. Lee, Diana W. Bianchi, Sabina Khantsis, and Monica Duran-Martinez
- Subjects
Pluripotent Stem Cells ,0301 basic medicine ,Down syndrome ,Chromosomes, Human, Pair 21 ,Bioinformatics ,Article ,03 medical and health sciences ,Cognition ,0302 clinical medicine ,Intervention (counseling) ,medicine ,Animals ,Humans ,Molecular Biology ,business.industry ,Brain ,Translation (biology) ,medicine.disease ,Clinical trial ,Disease Models, Animal ,Phenotype ,030104 developmental biology ,Molecular Medicine ,Down Syndrome ,Cognition Disorders ,business ,030217 neurology & neurosurgery - Abstract
While preclinical studies have reported improvement of behavioral deficits in the Ts65Dn mouse model of Down syndrome (DS), translation to human clinical trials to improve cognition in individuals with DS has had a poor success record. Timing of the intervention, choice of animal models, strategy for drug selection, and lack of translational endpoints between animals and humans contributed to prior failures of human clinical trials. Here, we focus on in vitro cell models from humans with DS to identify the molecular mechanisms underlying the brain phenotype associated with DS. We emphasize the importance of using these cell models to screen for therapeutic molecules, followed by validating them in the most suitable animal models prior to initiating human clinical trials.
- Published
- 2020
- Full Text
- View/download PDF